What the FDA actually cites when it inspects a trial

FDA warning letters to clinical trials read like variations on a short list. Year after year, the same handful of failures account for most of what the agency cites. Knowing that list is useful in two directions: it tells you where trials actually break, and it tells you which parts of the job the whole enforcement system is built to protect.

The recurring citations

For clinical investigators, the site physicians who draw the most inspections, the violations cluster in a consistent order:

• Failure to follow the protocol. The single most common citation. It covers enrolling ineligible subjects, dosing errors, and randomization or blinding failures. In one 2025 letter, an investigator was cited for enrolling subjects whose BMI fell outside the inclusion criteria.
• Failure to keep adequate and accurate records. The case histories that prove what happened are missing, incomplete, or contradictory.
• Failure to protect subjects and obtain proper informed consent. In a 2025 pediatric case, an investigator was cited for consent problems including failure to verify legal guardianship.
• Failure to report adverse events on time. A 2026 letter cited an investigator for reporting serious adverse events to the sponsor weeks or months late, against a protocol requiring 24 hours.
• Failure to submit an IND when one was required, and failure to account for the investigational product.

The list barely changes from year to year, which is itself the finding. These are not exotic failures. They are the fundamentals of running a trial, cited over and over because they are hard to do perfectly under real-world pressure.

Why the consistency matters

When the same failures recur every year, they stop being individual mistakes and start being a map of where the work is structurally hard. Protocol adherence, contemporaneous record-keeping, proper consent, and timely safety reporting are exactly the tasks that get squeezed when a site is understaffed, a coordinator is stretched across too many studies, or a monitor visits too rarely to catch drift early. The citation list is, read one way, a list of what happens when clinical research is under-resourced.

What it means for the people doing it

For workers, the recurring citations point straight at where the value is. The roles that prevent these failures, the rigorous CRA who catches a protocol deviation before it compounds, the coordinator who documents in real time, the quality staff who keep consent and records airtight, are the roles the entire regulatory apparatus exists to reward. When the FDA cites inadequate monitoring or sloppy records, it is, in effect, saying these functions were not resourced enough. That is a workforce argument hiding inside an enforcement document.

What the letters cannot tell you

FDA warning letters name the violation and the site. They do not tell you the conditions behind it: whether the cited investigator was drowning in studies, whether the monitoring that should have caught the problem was cut to save money, or what the remediation did to the team afterward. Those are the working conditions that turn a stretched site into a cited one, and they live only with the people who were there. If you have worked a site through an inspection or a finding, that context is worth more than the letter. Share what you can, and add your datapoint.